Finance

Lists
KROS:NASDAQ
Keros Therapeutics Inc
10,23 USD
+1,49%
(+0,15) 1D
13-ноя., 15:13:52 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KROS...
Open
10,06 USD
High
10,30 USD
Low
9,55 USD
Mkt. cap
200,76 млн
Avg. vol.
186,70 миң
Volume
72,74 миң
52-wk high
22,55 USD
52-wk low
8,98 USD
EPS
-2,83 USD
Beta
1,13
Shares outstanding
19,62 млн
No. of employees
87
Open
10,06 USD
High
10,30 USD
Low
9,55 USD
Mkt. cap
200,76 млн
Avg. vol.
186,70 миң
Volume
72,74 миң
52-wk high
22,55 USD
52-wk low
8,98 USD
EPS
-2,83 USD
Beta
1,13
Shares outstanding
19,62 млн
No. of employees
87
News stories
From web sources and news partners
Zacks
Zacks
·
1 күн мурун
New Strong Buy Stocks for November 12th
About Keros Therapeutics Inc
CEO-
Employees87
Founded2015
HeadquartersЛексингтон, Массачусетс, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Websitekerostx.com
Analyst ratings
Based on 3 analysts giving stock ratings to KROS in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for KROS in the last 3 months.
Highest
Current 10,23 USD
20,00 USD (+95,50%)
Average
18,00 USD (+75,95%)
Lowest
16,00 USD (+56,40%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yun Zhong
Wedbush
Hold
Maintained
16,00 USD
+56,4%
11/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
20,00 USD
+95,5%
11/06/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
18,00 USD
+76%
09/02/2026
Jason Zemansky
Bank of America Securities
Hold
Reiterated
17,00 USD
+66,2%
08/11/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
08/04/2026
Thomas Smith
Leerink Partners
Buy
Maintained
23,00 USD
+124,8%
08/04/2026
Nicholas Lorusso
TD Cowen
Hold
Reiterated
-
-
08/04/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/15/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
27,00 USD
+163,9%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
30,00 USD
+193,3%
03/06/2026
Tiago Fauth
Raymond James
Buy
Maintained
20,00 USD
+95,5%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
385,00 миң
367,00 миң
-
40,01 млн
Cost of goods sold
17,81 млн
16,10 млн
22,33 млн
20,49 млн
Cost of revenue
17,81 млн
16,10 млн
22,33 млн
20,49 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11,74 млн
10,15 млн
8,61 млн
6,70 млн
Operating expense
11,74 млн
10,15 млн
8,61 млн
6,70 млн
Total operating expenses
29,56 млн
26,24 млн
30,94 млн
27,19 млн
Operating income
-29,17 млн
-25,88 млн
-30,94 млн
12,82 млн
Other non operating income
-539,00 миң
-
-60,00 миң
-
EBT including unusual items
-24,98 млн
-23,71 млн
-28,71 млн
14,92 млн
EBT excluding unusual items
-24,88 млн
-23,71 млн
-28,71 млн
14,92 млн
Income tax expense
-1,51 млн
-
-
772,00 миң
Effective tax rate
6,06%
-
-
5,17%
Other operating expenses
-
-
-
-
Net income
-23,46 млн
-23,71 млн
-28,71 млн
14,15 млн
Net profit margin
-6 093,77%
-6 459,95%
-
35,37%
Earnings per share
-0,86
-1,21
-1,45
0,70
Interest and investment income
4,02 млн
2,34 млн
2,29 млн
2,28 млн
Interest expense
-
-
-
-
Net interest expenses
4,02 млн
2,34 млн
2,29 млн
2,28 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-28,77 млн
-25,47 млн
-30,54 млн
13,20 млн
Gain or loss from assets sale
1,00 миң
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору